Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIO·NASDAQ

$27.68

-1.1%
HealthcareBiotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.65B
EPS-7.1200
P/E Ratio-3.89
Earnings Date07/30/2026

agio

Effect of Foreign Exchange Changes on Cash

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. Competitors Analysis of Effect of Foreign Exchange Changes on Cash

AGIO · NASDAQ
CompanyEffect of Foreign Exchange Changes on Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
ETNB logo
89bio, Inc.
NASDAQ:ETNB
0.00
N/AN/AN/A
15.00K
N/A-20.8%N/A
-3.50M
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
18.04M
357.9%N/AN/A
Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. Fair Value Envelope

AGIO · NASDAQ

Our analysis suggests that AGIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.68, this represents a potential HIDDEN relative to our calculated worth for Agios Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $27.68